Why colds and flu cause sore throats but RSV might not
When you catch a cold or the flu, a sore throat is often a symptom, making swallowing and talking uncomfortable. With Respiratory Syncytial Virus (RSV), symptoms in adults and older, healthy children can typically mimic the common cold.1
Cepacol, known for its sore throat lozenges, hot medication, and now new raspberry-flavoured effervescent, answers the question: why do colds and flu commonly lead to sore throats, whereas RSV might not?
How colds and flu differ from RSV
Influenza, commonly known as the flu, and the common cold are both contagious respiratory illnesses, but they are caused by different viruses. The flu is caused strictly by influenza viruses, while the common cold can be triggered by a variety of viruses, including rhinoviruses, parainfluenza viruses, and certain coronaviruses.
When you're down with the flu, a cold, or another infection, your body springs into action to fight off the invaders. This immune response involves releasing white blood cells to combat the infection, leading to inflammation. It's this inflammation that often leaves your muscles feeling achy and sore.
Alongside body aches, you may also experience symptoms like fever, weakness, fatigue, shivering, or changes in body temperature, as well as other cold and flu-like symptoms.
RSV, on the other hand, tends to behave differently. While it can cause upper respiratory symptoms like a congested or runny nose, dry cough, low-grade fever, sneezing, headache and sore throat, RSV may move deeper into the respiratory system, affecting the lower parts like the lungs. This can lead to conditions such as bronchiolitis and pneumonia.
Why does this matter?
Understanding the differences between colds, flu, and RSV can help in identifying the illness you're dealing with, the treatment needed, and how long your recovery will likely be. Always consult your health care practitioner to determine your illness and treatment options.
Colds: The common cold is a contagious respiratory illness caused by a virus, usually with milder symptoms than flu. People with colds are more likely to have a runny or stuffy nose, which generally doesn't result in serious health problems.
Flu: Influenza (flu) is also a contagious respiratory illness, but is caused by a different virus. Flu is caused by influenza viruses only, and in general, flu is worse than the common cold; symptoms are typically more intense and begin more abruptly. The signs and symptoms of flu can include fever or feeling feverish/chills, cough, sore throat, runny or stuffy nose, muscle or body aches, headaches, and fatigue (tiredness).
RSV: Symptoms most commonly appear approximately four to six days after exposure to the virus, with most people usually recovering from RSV within one to two weeks. Self-care measures are usually all that's needed to relieve any discomfort. The Centres for Disease Control and Prevention recommends that adults aged 60 and older get an RSV vaccine.
Protecting yourself and others
Regardless of the specific virus, practising good hygiene can help prevent the spread of these infections. Practising good hygiene is a great start. Wash your hands frequently with soap and water for at least 20 seconds and use alcohol-based hand sanitisers.
Cover your mouth and nose with a tissue or the crook of your elbow when you cough or sneeze. Regularly disinfect commonly touched surfaces and objects like doorknobs and light switches. Staying home when you're sick not only helps you recover but also prevents spreading illness to others.
Beat the scratch with Cepacol new raspberry-flavoured effervescent
Don't let a sore throat slow you down. Cepacol understands that when discomfort hits, you need relief to keep up with your busy life. That's why we've developed a range of products designed to soothe your throat and get you back to feeling your best, including our latest innovation: the Cepacol Effervescent – a fantastically fizzy, raspberry-flavoured effervescent provides double-duty relief for the whole family (6+).
Cepacol® Effervescent5 helps to relief symptoms of cold and flu such as sore throat, nasal congestion, sneezing and cough, opening of the airways, thinning of mucus and providing relief of coughs associated with inflammation of the airways. It also supports the immune function within the upper respiratory tract and provides antioxidant support for the maintenance of good health.
In addition to Cepacol®'s newly launchedraspberry-flavoured effervescent5, the Cepacol® range includes cough and cold syrup9, Plus cough and cold syrup10 specifically designed for nighttime relief, a throat spray11 and throat gargle12, Medsip, a hot medicated drink3&4 in either ginger or honey lemon flavours, and antibacterial throat lozenges2 in four great tasting flavours – regular, black current, honey & lemon and menthol.
So, when you're dealing with a stuffy nose, cough and scratchy throat, remember, there's a Cepacol® for that!
Embrace the Winter Warrior within, with Cepacol®
As we brace ourselves for the winter months, it's wise to be prepared. Adcock Ingram's Winter Warriors 2025 Campaign offers a range of products aimed at combating common cold and flu symptoms. With brands like Cepacol®, Panado®, Compral®, ProbiFlora™, Gummy® Vites and ViralGuard™, you can arm yourself and your loved ones against the seasonal sniffles.
Cepacol®'s range of products is now available at leading pharmacies and retailers nationwide. For more information and references, visit www.cepacol.co.za and join the conversation on Facebook.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Citizen
23-07-2025
- The Citizen
Miracle recovery for baby on life support at Waterfall City Hospital
Baby's life was at risk due to a serious chest infection but expert care and extracorporeal membrane oxygenation helped him recover. When a two-month-old baby's chest infection suddenly turned serious, he was not breathing properly and was slipping in and out of consciousness, says his mother, remembering the horrifying realisation. 'I knew we had to try to keep him awake. He needed urgent medical care and so I drove with Nkateko on my lap to the emergency department at Netcare Waterfall City Hospital. 'I don't remember parking the car – I just rushed him inside and they immediately put him on oxygen,' said Nthabiseng Mlangeni. Baby's chest infection suddenly turned serious Nkateko was first admitted to the paediatric unit and his mother was able to remain with her son, rooming with him. After several days in the hospital, Nkateko was again struggling to breathe, despite medication and physiotherapy to help clear mucus from his lungs. Doctors transferred Nkateko, whose name means 'blessing', to the paediatric intensive care unit (PICU) under the care of paediatric intensivist Dr Palesa Monyake. ALSO READ: 'My hell after a botched op': Mother's life in ruins after botched birth surgery 'In the PICU, they started him on high-flow oxygen and Dr Monyake explained the unfamiliar environment to us, the treatment Nkateko was receiving and how they were monitoring his condition every minute. 'It was the hardest thing to leave my two-month-old baby and go home because parents can't room with their children in the high-care environment,' Mlangeni said. 'I did not sleep at all that night, between worrying about Nkateko and anxiously expecting a call from the hospital at any moment. It was one of many sleepless nights in the weeks ahead, but we came to trust the PICU team implicitly.' Swell up in response to infection The next day, Nkateko's vital statistics suddenly dropped further, requiring the baby to be placed on a ventilator, then on an oscillator to support his breathing. 'He started to swell up in response to the infection and it was extremely frightening to see all these tubes sticking out of him. 'Our families in Gauteng and other relatives travelled from different provinces to support us. We knew it was a very serious situation, and we prayed constantly,' Mlangeni said. ALSO READ: Smile Foundation's 25 years of changing lives Monyake said Nkateko was one of several children admitted to the PICU requiring critical care for respiratory syncytial virus (RSV) so far this year. 'Babies' immune systems have not had the time to build up resistance to the many common germs such as RSV that generally would not cause serious illness among older children or adults,' she said. 'It is rare to put a child on extracorporeal membrane oxygenation, however, this RSV season has been particularly brutal, and we are grateful this lifesaving option is available for our patients who are in the critical situation that Nkateko faced.' Life-threatening circumstances Cardiothoracic surgeon Dr Sharmel Bhika said extracorporeal membrane oxygenation is a form of life support in which specialised equipment artificially performs the functions of the heart and lungs, giving them a chance to heal. It is only considered in life-threatening circumstances for such young children. 'Extracorporeal membrane oxygenation is a valuable lifeline when other forms of ventilation are no longer proving effective. Without this intervention Nkateko may not be with us today. 'He required maximum mechanical ventilatory support and was not reaching targets for adequate oxygenation. ALSO READ: Baby girl's life saved by surgery 'Extracorporeal membrane oxygenation was a clear indication in Nkateko's case with his rapid deterioration and increased demand on mechanical ventilatory support,' Bhika said. Mlangeni said: 'Although I felt like I was at breaking point, we remained prayerful. We also found comfort and support from the nurses and the unit manager Sister Jabulile Nxumalo. 'Every nurse who looked after Nkateko did so with so much care and they really supported us. The doctors, especially Dr Monyake, who was so supportive and prayed with us, and the extracorporeal membrane oxygenation doctors who ensured that we were updated throughout the process, and the families of other children who were also being cared for in the PICU.' Every nurse who looked after Nkateko did so with care The baby boy showed remarkable resilience as he fought for survival. 'Nkateko gradually improved enough that we could consider transitioning after three weeks back onto conventional ventilation,' Bhika said. Monyake added: 'This little boy had us so worried, it was an emotional roller-coaster, but his parents were amazing. They remained positive and drew strength from their faith.' NOW READ: Bara hospital: The good, bad and ugly
Daily Maverick
22-07-2025
- Daily Maverick
New respiratory virus vaccine a game changer for babies, but cost remains a barrier
A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector, but not yet in public clinics. The country's advisory group on immunisations has recommended making it available to all pregnant women. This proposal is now under review by the national Department of Health. Like the common cold, respiratory syncytial virus (RSV) is highly contagious. It is spread through airborne respiratory droplets and contact with contaminated surfaces. RSV infection is often difficult to distinguish from the common cold. This is because it has similar symptoms and typically clears up without medical intervention. However, in some cases, it can become serious enough to need medical care or even a hospital stay, especially for babies under six months old, who are the most vulnerable. Severe illness typically affects the lower respiratory tract and can lead to bronchiolitis or pneumonia, which can cause difficulty breathing. Babies who are admitted to hospital may need extra help, such as oxygen to help them breathe, fluids through a drip to keep them hydrated, and in serious cases, a machine to help them breathe. RSV is a major cause of illness and death in children under five, especially in the first six months of life in low- and middle-income countries. A recent global study estimated that in 2019, RSV was responsible for just over 100,000 deaths in children under five. This made up 2% of all deaths in this age group, and 3.6% of deaths in babies aged 28 days to six months. Nearly half of all RSV-related deaths occurred in babies under six months, and 97% of these deaths were in low- and middle-income countries. A new vaccine to prevent RSV in infants A new vaccine provides infants with significant protection against severe RSV disease. It is given to pregnant women during their third trimester of pregnancy (from week 28 to birth). Protective antibodies elicited by the vaccine are transferred from the mother to the foetus across the placenta. Currently, only one pharmaceutical company, Pfizer, markets the maternal RSV vaccine. It is sold under the brand name Abrysvo. It is also known by the generic name RSVpreF. The South African Health Products Regulatory Authority approved Abrysvo in December 2024, and it became available in the country's private sector in 2025. The effectiveness of the vaccine in preventing severe RSV disease was first announced in November 2022. This followed early positive results from the Maternal Immunisation Study for Safety and Efficacy (Matisse) which was conducted in 18 countries, including South Africa. It showed that infants born to mothers who received the maternal RSV vaccine had an 82.4% lower risk of developing severe RSV-associated lower respiratory tract illness within the first 90 days of life than infants whose mothers received a placebo. At 180 days after birth, the vaccine was 70% effective in reducing the risk of severe RSV illness. Recommendations from health agencies By September 2023, the United States Centers for Disease Control and Prevention recommended giving the RSV vaccine to pregnant women to help protect their babies from severe illness. One year later, in September 2024, the World Health Organization (WHO) recommended that all countries introduce the maternal RSV vaccine. It also recommended an alternative for babies whose mothers weren't vaccinated: a single dose of the monoclonal antibody nirsevimab, ideally given at birth or before discharge from the birthing facility. While acknowledging cost limitations, the WHO noted that if not given at birth, the antibody could be given at the baby's first health visit. In countries offering it only during RSV season, older infants can receive the dose just before their first season begins. Nirsevimab is not yet registered in South Africa and the cost is expected to be a barrier to its rollout in the country. South Africa has not yet adopted formal guidelines for the broad use of the maternal RSV vaccine. But the National Advisory Group on Immunisations recently recommended that the national Department of Health introduce the RSVpreF vaccine into the public immunisation programme as a single-dose vaccination for all pregnant women. This recommendation was outlined in a letter to Health Minister Dr Aaron Motsoaledi on 23 April 2025. 'In line with the National Advisory Group on Immunisations' terms of reference which govern the committee's work, the department is currently assessing the cost and other implications of RSV vaccine introduction with relevant senior managers and other stakeholders,' the health department's spokesperson, Foster Mohale, told Spotlight. 'Feeback will be provided to the group's chairperson once a decision regarding possible introduction has been reached,' he added. Price remains a barrier Pfizer is selling Abrysvo in South Africa as a single-dose vaccine, priced at R3,746 ($US 210), excluding VAT and dispensing fees. This price for the private sector is significantly higher than the government's threshold for broad roll-out, according to a cost-effectiveness analysis of RSV immunisation. The analysis found that at a price of US$5 (about R90) per dose, the vaccine would offer savings to South Africa's health sector. But if the price exceeds US$40 (about R700) per dose then widespread procurement may no longer be feasible. Pfizer's pricing of Abrysvo in South Africa's private sector is 'disappointingly high', Shabir Madhi, Professor of Vaccinology at the University of the Witwatersrand, told Spotlight. He added that he thought 'something has gone awry in terms of pricing of the vaccine in South Africa'. He pointed out that the Pan American Health Organization, which works to improve the health and quality of life, secured a price of US$49 (about R800) per dose for procurement of the vaccine for use in Latin American countries. 'It does tell us that certainly the cost of producing a vaccine is nowhere close to $200 if the same vaccine is being provided at $49 to the Pan American Health Organization,' said Madhi. Pfizer did not answer questions from Spotlight about whether a lower price would be offered to the public sector, but a company spokesperson said: 'We are committed to working with the government and healthcare stakeholders to ensure our medicines and vaccines are available to all those who need them in South Africa.' 'There has been engagement with Pfizer, and they have indicated that the [public sector] price of the maternal RSV vaccine is likely to align with current Pan American Health Organization pricing,' said Mohale. Apart from pricing, he said that introducing the maternal RSV vaccine involved several other health system considerations. 'A comprehensive implementation guideline will be needed to address areas such as monitoring and evaluation, supply chain capacity, healthcare worker training, and demand creation to ensure effective and sustainable rollout,' said Mohale. Fortunately, South Africa, unlike some other countries, already had established vaccine programmes for pregnant women, said Madhi. 'We've been vaccinating pregnant women with the tetanus vaccine for decades now, and as of last year we actually introduced the acellular pertussis, tetanus, diphtheria combination vaccine for pregnant women,' he said. DM
TimesLIVE
17-07-2025
- TimesLIVE
Government considering providing vaccine to protect babies from respiratory syncytial virus
A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on immunisations has recommended availing it to all pregnant women. This proposal is now under review by the national department of health. Like the common cold, respiratory syncytial virus (RSV) is highly contagious. It is spread through airborne respiratory droplets and contact with contaminated surfaces. RSV infection is often difficult to distinguish from the common cold. This is because it has similar symptoms and typically clears up without medical intervention. However, in some cases, it can become serious enough to need medical care or even a hospital stay, especially for babies under six months old, who are most vulnerable. Severe illness typically affects the lower respiratory tract and can lead to bronchiolitis or pneumonia, which can cause difficulty breathing. Babies who are hospitalised may need extra help, such as oxygen to help them breathe, fluids through a drip to keep them hydrated, and in serious cases, a machine to help them breathe. RSV is a major cause of illness and death in children under five, especially in the first six months of life in low- and middle-income countries. A recent global study estimated that in 2019, RSV was responsible for just over 100,000 deaths in children under five. This made up 2% of all deaths in this age group, and 3.6% of deaths in babies aged 28 days to six months. Nearly half of all RSV-related deaths occurred in babies under six months, and 97% of these deaths were in low- and middle-income countries. A new vaccine provides infants with significant protection against severe RSV disease. It is given to pregnant women sometime during their third trimester of pregnancy (from week 28 to birth). Protective antibodies elicited by the vaccine are transferred from the mother to the foetus across the placenta.
